IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Journal of Allergy and Clinical Immunology: In Practice Année : 2019

IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy

Claus Bachert
Oscar Palomares
Pascal Pfister
  • Fonction : Auteur
Ioannis Kottakis
  • Fonction : Auteur
Xavier Jaumont
  • Fonction : Auteur
Simon Francis Thomsen

Résumé

Allergic asthma often coexists with different pathological conditions, called multimorbidities, that are mostly of allergic nature and share a common underlying inflammatory pathophysiological mechanism. Multimorbidities of allergic asthma may influence asthma control, its severity, and patients' response to treatment, and contribute to the overall socioeconomic burden of the disease. Immunoglobulin E (IgE) is known to play a central role in the pathogenesis of various allergic diseases, including asthma. Thus, IgE-mediated immunologic pathways present an attractive target for intervention in asthma and multimorbidities. In this review, we discuss the most frequently reported IgE-mediated multimorbidities in allergic asthma, including allergic rhinitis, rhinoconjunctivitis, atopic dermatitis, vernal keratoconjunctivitis, chronic rhinosinusitis with nasal polyps, food allergies, and allergic bronchopulmonary aspergillosis. Omalizumab is a recombinant humanized monoclonal antibody against IgE and has been in use to treat allergic asthma for more than a decade. We comprehensively review the clinical evidence for omalizumab in the treatment of the aforementioned multimorbidities in allergic asthma.

Dates et versions

hal-02869527 , version 1 (16-06-2020)

Identifiants

Citer

Marc Humbert, Jean Bousquet, Claus Bachert, Oscar Palomares, Pascal Pfister, et al.. IgE-Mediated Multimorbidities in Allergic Asthma and the Potential for Omalizumab Therapy. Journal of Allergy and Clinical Immunology: In Practice, 2019, 7 (5), pp.1418-1429. ⟨10.1016/j.jaip.2019.02.030⟩. ⟨hal-02869527⟩
21 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More